Applied DNA Sciences Files 8-K on Exit Costs

TL;DR

APDN filed an 8-K for exit costs as of Sept 30, 2025. Watch for restructuring.

AI Summary

Applied DNA Sciences, Inc. filed an 8-K on October 6, 2025, reporting on cost associated with exit or disposal activities as of September 30, 2025. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company was formerly known as ProHealth Medical Technologies Inc., DCC Acquisition Corp., and Datalink Capital Corp/TX/.

Why It Matters

This filing indicates potential restructuring or divestiture activities within Applied DNA Sciences, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Filings related to exit or disposal activities can signal financial distress or significant strategic shifts, warranting closer examination.

Key Players & Entities

• Applied DNA Sciences, Inc. (company) — Registrant
• ProHealth Medical Technologies Inc. (company) — Former Company Name
• DCC Acquisition Corp. (company) — Former Company Name
• Datalink Capital Corp/TX/ (company) — Former Company Name
• September 30, 2025 (date) — Date as of which activities are reported
• October 6, 2025 (date) — Filing Date

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value APDN The Nasdaq Stock Mar
• $1.4 million — regate pre-tax charges of approximately $1.4 million in connection with the reduction-in-for
• $2.9 million — nnualized cost savings of approximately $2.9 million. The estimated charges that the Company

Filing Documents

• tm2528084d1_8k.htm (8-K) — 26KB
• tm2528084d1_ex99-1.htm (EX-99.1) — 13KB
• tm2528084d1_ex99-1img01.jpg (GRAPHIC) — 22KB
• 0001104659-25-097097.txt ( ) — 235KB
• apdn-20250930.xsd (EX-101.SCH) — 3KB
• apdn-20250930_lab.xml (EX-101.LAB) — 33KB
• apdn-20250930_pre.xml (EX-101.PRE) — 22KB
• tm2528084d1_8k_htm.xml (XML) — 3KB

05 Costs Associated with Exit or Disposal Activities

Item 2.05 Costs Associated with Exit or Disposal Activities. On September 30, 2025, the Board of Directors of Applied DNA Sciences, Inc. (the " Company ") authorized, and its officers implemented, a restructuring plan pursuant to which the Company will reduce overall operating expenses to focus resources on its previously announced BNB-focused treasury strategy. The restructuring plan includes a reduction of the Company's current workforce by sixteen employees, or approximately 60%. The Company estimates that it will incur aggregate pre-tax charges of approximately $1.4 million in connection with the reduction-in-force, primarily consisting of severance payments, employee benefits, and related costs. The Company expects that the reduction-in-force will be substantially completed by the end of October 2025 and that the associated charges will be recorded in the first quarter of fiscal 2026. The Company estimates that the restructuring will result in annualized cost savings of approximately $2.9 million. The estimated charges that the Company expects to incur are subject to a number of assumptions, and actual results may differ materially from these estimates. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the restructuring plan.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 6, 2025, the Company issued a press release announcing that it will change its ticker symbol on the Nasdaq Capital Market from "APDN" to "BNBX" effective at the opening of trading on Tuesday, October 7, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company's belief that restructuring will reduce overall operating expenses, the future success of its Linea DNA and Linea IVT platforms and its treasury strategy and future reductions in operating expenses. All forward-looking no obligation to update forward-looking statements to reflect future events or circumstances. Capitalized terms shall have the meanings ascribed to such terms in the Current Report on Form 8-K. Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release, dated October 6, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 6, 2025 APPLIED DNA SCIENCES, INC. By: /s/ Beth Jantzen Name: Beth Jantzen Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR